














580What Is the Role for Donor Natural Killer Cells after
Nonmyeloablative Conditioning?
Frederic Baron,1 Effie W. Petersdorf,2,3 Ted Gooley,2,3 Brenda M. Sandmaier,2,3
Mari Malkki,2,3 Thomas R. Chauncey,2,3,4 David G. Maloney,2,3 Rainer Storb2,3We investigated the impacts of the tempo of early (days 14, 28, and 42) donor T cell and natural killer (NK)
cell engraftment, missing recipient killer cell immunoglobulin-like receptor (KIR) ligands, and numbers of do-
nor inhibitory and activating KIR genes on hematopoietic cell transplantation (HCT) outcomes in 282 pa-
tients with hematologic malignancies given nonmyeloablative conditioning. Modeling chimerism levels as
a continuous linear variable, we found that high early donor T cell chimerism was significantly associated
with acute graft-versus-host disease (aGVHD) (P 5 .01), whereas high donor NK cell chimerism levels
had no such association (P5 .38). Conversely, high donor NK cell chimerism levels were significantly asso-
ciated with low relapse risk (P 5 .0009), whereas no significant association was seen with high donor T cell
chimerism (P 5 .10). The qualitative associations between donor T cell and NK cell chimerism levels and
GVHD and relapse did not change after adjustment for the presence of recipient KIR ligands or numbers
of donor inhibitory or activating KIR genes. Our data indicate that prompt engraftment of donor NK cells
correlated with lessened risks of relapse, but not with GVHD, whereas the converse was true for T cells.
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Allogeneic hematopoietic cell transplantation
(HCT) after nommyeloablative conditioning relies
nearly exclusively on graft-versus-tumor effects for tu-
mor eradication [1-6]. Although it is generally accepted
that graft-versus-tumor effects after HLA-identical
HCT mainly result from T cells [7-9], observations
by the Perugia group showed that after HLA-haploi-
dentical HCT, graft-versus-host natural killer (NK)
cell reactivity was associated not only with less relapse
in patients with acute myelogenous (but not lympho-
blastic) leukemia (AML), but also with less graft rejec-
tion and less acute graft-versus-host disease (aGVHD)
[10]. These findings have sparked renewed interest in
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6/j.bbmt.2009.01.018NK cell activities are thought to be regulated by
a quantitative balance between inhibitory signals medi-
atedby inhibitorykiller cell immunoglobulin-like recep-
tors (KIRs) and CD94/NKG2A, and by activating
signals mediated by the natural cytotoxicity receptors
(NCRs) NKG2D and DNAX accessory molecule-1
(DNAM-1, CD226) [11]. KIRs recognize allotypic de-
terminants that are shared by different HLA class 1 al-
leles; KIR2/DL2 and KIR2/DL3 recognize HLA-C
group 1 alleles, KIR2/DL1 recognizes HLA-C group
2, and KIR3/DL1 recognizes HLA-Bw4 alleles [11].
Conversely, CD94/NKG2A recognizes overall expres-
sion of HLA class 1 molecules on target cells through
HLA-E. Although HLA and KIR genes are inherited
independently, clonal analyses have demonstrated that
in healthy individuals, each NK cell either expresses at
least one inhibitory receptor for self HLA (either KIR
or the nonspecific CD94/NKG2A receptor) or is devel-
opmentally immature [12,13].
After transplantation, donor NK cells arising from
hematopoietic stem cells (HSCs) regenerate the same
KIR repertoire as the donor, [14] leading to a high fre-
quency of graft-versus-host reactive NK cells in those
recipients who lack ligands for donor NK cell KIRs
[15]. Such alloreactive NK cells are detectable for
only a few months after HCT [15]; thereafter, they be-
come tolerant to the host, likely in part through expres-
sion of KIRs specific to the recipient HLA [16]. NK
alloreactivity has been associated with graft-versus-
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matched HCT [10,16-19].
In previous work, we analyzed the correlations
between the tempo of engraftment of various periph-
eral blood stem cell (PBSC) subpopulations and
HCT outcomes in 120 patients with various hemato-
logic malignancies who underwent HCT after non-
myeloablative conditioning [20]. We found a strong
suggestion that rapid establishment of high levels of
donor NK cell chimerism between days 14 and 100 af-
ter HCT predicted better progression-free survival
(PFS) [20]. In the present study, we examined the im-
pact of both early donor T cell and NK cell chimerism
levels on transplantation outcomes in the context of re-
cipient HLA ligand and donor KIR receptor genetic
data in 282 patients with cancer who underwent
HCT from either a related or an unrelated donor after
a minimal-intensity conditioning regimen that in-
cluded 2 Gy of total body irradiation (TBI).PATIENTS AND METHODS
Patients and Donors
Data from 282 patients who underwent allogeneic
HCT after nonmyeloablative conditioning at the Fred
Hutchinson Cancer Research Center, University of
Washington Medical Center, Children’s Hospital
and Regional Medical Center, and the Veterans Affairs
Medical Center (all in Seattle) between March 1998
and November 2006 were included in this study.
Patient characteristics are summarized in Table 1.
Median patient age was 54 years (range, 5 to 74 years).
Diagnoses included hematologic malignancies (n 5
274) and solid tumors (n 5 8). Patients were classified
as having indolent or aggressive disease, as character-
ized previously [21]. A total of 152 patients received
grafts from HLA-identical related donors, 1 from a 1
HLA-A antigen–mismatched related donor, 95 from
HLA-A, -B, -C, -DR, and -DQ allele–matched unre-
lated donors (URDs), and 34 from 1 HLA class I
allele– and/or 1 antigen-mismatched URDs. Comor-
bidities at the time of HCT were assessed using the
HCT comorbidity index (HCT-CI) score [22]. Pro-
spective research protocols were approved by the
Fred Hutchinson Cancer Research Center’s Institu-
tional Review Board for the 4 participating institu-
tions. Informed consent was obtained from all
patients.Treatment and Evaluation
A total of 54 recipients of related grafts were condi-
tioned with 2 Gy TBI alone [3], whereas the remaining
99 recipients of related grafts and all recipients of unre-
lated grafts also received fludarabine (Flu) 30 mg/m2/
day on days 24, 23, and 22 before HCT [3,4,23-25]. Donor granulocyte colony-stimulating factor
(G-CSF)–mobilized peripheral blood mononuclear
cell (G-PBMC) grafts (n 5 271) or bone marrow
(BM) grafts (n 5 11) were infused without processing
on day 0. Postgrafting immunosuppression included
mycophenolate mofetil (MMF) and cyclosporine
(CsA) or tacrolimus in all patients, as described previ-
ously [3,4,23,25,26].
Grading and treatment of aGVHD and chronic
GVHD (cGVHD)were performed according to estab-
lished criteria [27]. Disease-dependent restaging after
HCT occurred monthly for the first 3 months and
then at 6 months, 1 year, and yearly thereafter. Persis-
tent or progressive malignancies in the absence of
GVHDwere treated by rapid tapering and discontinu-
ation of immunosuppression, and 24 patients received
donor lymphocyte infusion (DLI) [28]. Eight addi-
tional patients with low or failing T cell chimerism
received DLI 2 days after receiving pentostatin (4 g/
m2) aimed at preventing graft rejection, as reported
previously [29].
Relapse and progression were defined according to
the criteria of Kahl et al. [6] and Rotta et al. [30].Relapse
was defined as recurrence of malignancy based on one
ormore of the following parameters:marrowmorphol-
ogy, flow cytometry, cytogenetic studies (including
fluorescein in situ hybridization [FISH]), electropho-
resis, immunofixation assays, polymerase chain reac-
tion (PCR)-based assays for disease markers, and
imaging results. Disease progression was defined as a $
50% increase in disease burden or a 25% increase in
any disease marker for patients with multiple myeloma
(MM).
Chimerism Analyses
The different peripheral blood subpopulations
were sorted by 3-color flow cytometry using a Vantage
SE cytometer (BD, San Jose, CA). Cell types were
defined as follows: T cell, CD31CD56- sidescatterlow;
NK cell, CD561CD3-CD14- sidescatterlow. Percent-
ages of donor chimerism in the different blood cell
populations were assessed using PCR-based analyses
of polymorphic minisatellite or microsatellite regions
(VNTR/STR) or FISH for X and Y chromosomes if
patients and donors were sex-mismatched, as reported
previously [3,20].
HLATyping, KIR Genotyping, and the Missing
KIR Ligand Algorithm
Sequence-specific oligonucleotide hybridization
and/or sequencing-based typing methods were used to
define exons 2 and 3 of HLA-A, -B, and -C alleles and
exon 2 of -DRB1 and -DQB1 alleles in all unrelated do-
nor–recipient pairs. Pairs with the sameHLA-A, -B, -C,
-DRB1, and -DQB1 alleles were defined as ‘‘10/10’’ al-
lele matched; all other pairs were defined by the number
Table 1. Patient, Disease, and Transplantation Characteris-
tics (n 5 282)
Characteristic Value
Median patient age, years (range) 54 (5-74)
Recipient sex, male/female, n (%) 182 (65)/100 (35)
Median donor age, years (range) 45 (19-78)
Donor sex, male/female, n (%) 147 (52)/135 (48)
Diagnosis, n (%)
Acute myelogenous leukemia 63 (22.3)
Acute lymphoblastic leukemia 8 (2.8)
Chronic myelogenous leukemia 15 (5.3)
Chronic lymphocytic leukemia 33 (11.7)
Myelodysplastic syndrome 31 (11.0)
Multiple myeloma 44 (15.6)
Non-Hodgkin lymphoma 52 (18.4)
Hodgkin disease 25 (8.9)
Waldenstro¨m macroglobulinemia 3 (1.0)
Renal cell carcinoma 7 (2.5)
Cervical cancer 1 (0.4)
Disease risk, n (%)
Indolent* 123 (44)
Aggressive† 159 (56)




One HLA-antigen mismatched 1 (0.4)
Unrelated
10/10 HLA allele-matched 95 (33.7)
One HLA-allele mismatched 16 (5.7)
One HLA-antigen mismatched 13 (4.6)
One HLA-antigen + 1 HLA allele
mismatched
5 (1.8)
Numbers of inhibitory genes on donor NK






Number of activating genes on donor NK








Hematopoietic stem cell source, n (%)
G-PBMC 271 (96)
Bone marrow 11 (4)
Conditioning regimen, n (%)
2 Gy TBI 54 (19)
2 Gy TBI + fludarabine 228 (81)
Cell dose,  106/kg recipient, median
(range)
CD34+ cells 7.8 (0.8-42.6)
T cells 312 (16-934)
Sustained engraftment/graft rejection, n (%) 264 (94)/18 (6)
Acute GVHD, n (%)
Grade 0/I 113 (40.1)
Grade II 127 (45.0)
Grade III 31 (11.0)
Grade IV 11 (3.9)
Chronic GVHD, n (%)
No 135 (48)
Yes 147 (52)
3-year overall survival (%) 50
3-year progression-free survival (%) 37
TBI indicates total body irradiation; GVHD, graft-versus-host disease;
KIR, killer cell immunoglobulin-like receptor.
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(Table 1). DNA for KIR genotyping was available for
264 of the 282 donors (94%). The presence or absence
of 10 KIR genes (2DL1, 2DL2, 2DL3, 3DL1, 2DL5,
2DS2, 2DS3, 2DS4, 2DS4-22bp deletion, and 2DS5)
was assessed using a commercial PCR–sequence-spe-
cific primers (SSP) kit (Invitrogen, Carlsbad, CA), fol-
lowing the manufacturer’s protocol. Typing for the
2DS1 gene was performed using previously published
PCR-SSP primers [31]. KIR pseudogenes (KIR2DP1
and 3DP1) were not typed. KIR framework genes
(KIR2DL4, KIR3DL2, and KR3DL3) are present in
all individuals [32] and thus were not genotyped. Recip-
ient HLA-A, -B, and -C alleles and donor KIR2DL1,
KIR2DL2/3, KIR3DL1, and KIR3DL2 loci were eval-
uated as follows: absence of recipient HLA-Bw4 epi-
topes in HLA-A and/or -B with the presence of donor
KIR3DL1; absence of recipient Cw3 epitopes (C1
group) in the presence of donor KIR2DL2/3; absence
of recipient Cw4 epitopes (C2 group) in the presence
of donor KIR2DL1, and absence of recipient HLA-
A3/A11 alleles/antigens in the presence of donor
KIR3DL2 [33]. The total numbers of donor-activating
KIR genes (2DS1, 2DS2, 2DS3, 2DS4, and 2DS5) and
of donor-inhibitory KIR genes (2DL1, 2DL2, 2DL3,
3DL1, and 2DL5) were determined for each pair.Statistical Analyses
Potential associations between chimerism levels
and pretransplantation/transplantation characteristics
were determined using the generalized estimating
equation method. The effects of the percentage of do-
nor chimerism on the incidence of rejection and
aGVHD were assessed using logistic regression, and
the effects on PFS, relapse, and nonrelapse mortality
(NRM) were assessed using Cox regression. The asso-
ciation betweenKIR genetics and outcome also was ex-
amined usingCox regression. In some cases, chimerism
was modeled as a time-dependent covariate (within the
first 42 days after HCT for relapse, NRM and PFS); in
other cases, the effects of chimerismvalues at a specified
timepoint on outcome (rejection and aGVHD) were
examined. Analyses of associations of chimerism level
and KIR genetics with relapse, NRM, and PFS were
adjusted for indolent/aggressive disease, HCT-CI
score, donor relationship, and previous autologous
HCT. The effects of KIR genetics on the association
between NK chimerism and outcome were assessed*Defined as acute myelogenous leukemia in first complete remission,
acute lymphoblastic leukemia in first complete remission, myelodysplas-
tic syndrome–refractory anemia, chronic myelogenous leukemia in first
chronic phase, chronic lymphoblastic leukemia, low-grade non-Hodgkin
lymphoma, multiple myeloma in partial or complete remission, andWal-
denstrom macroglobulinemia.
†All other diagnoses.
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the appropriate regression models. Spearman correla-
tion coefficients were estimated to evaluate the correla-
tions between donor cell subsets. P values from
regression models were derived from the Wald test.RESULTS
Kinetics of Donor Engraftment
Median donor T cell and NK cell chimerism levels
were 66% (range, 1% to 100%) and 78% (range, 3% to
100%), respectively, on day 14, 79% (range, 1% to
100%) and 90% (range, 2% to 100%) on day 28, and
81% (range, 1% to 100%) and 88% (range, 1% to
100%) on day 42. The Pearson correlation coefficient
between donor T cell and NK cell chimerism level was
0.60 on day 14, 0.76 on day 28, and 0.75 on day 42.Factors Affecting Kinetics of Donor
Engraftment
Transplantation/Pretransplantation Factors
High numbers of transplanted CD341 cells corre-
lated with high levels of donor T cell chimerism
(P 5 .002) and NK cell chimerism (P 5 .004) (Table
2). Furthermore, whereas high numbers of transplanted
T cells correlated closely with high levels of early donor
T cell chimerism (P 5 .004), the association with NK
cell chimerism was weaker (P5 .06). Patients receiving
bonemarrow grafts had lower levels of donorT cell chi-
merism (P\ .0001) and NK cell chimerism (P 5 .007)
compared with those receiving G-PBMCs. Patients
with lymphogenous malignancies had higher levels of
donor T cell chimerism compared with those with
myelogenous malignancies (P5 .0006) or solid tumors
(P 5 .007), although the associations between disease
category and donor NK cell chimerism level did not
reach statistical significance.
Associations between KIR/KIR ligand and kinetics
of donor NK cell engraftment
The absence of 1 ormore recipient ligands for donor
KIR did not have a statistically significant effect on aver-
age donor NK cell chimerism level. Specifically, the
average donor NK cell chimerism level on days 14, 28,
and42was5.6%lower inpatientswith all ligandspresent
comparedwith thosemissing1ormore ligands (P5 .23).
When the numbers of donor-inhibitory genes were
modeled as continuous linear variables, an increasing
number of genes was associated with decreased donor
NK cell chimerism, but the correlation was not statis-
tically significant (P 5 .11). Similarly, an increasing
number of donor-activating genes was associated with
lower chimerism levels, but this association also was
not statistically significant (P5 .10).Associations between Tempo of Donor Cell
Engraftment and HCTOutcome
Graft rejection
Eighteen of the 282 patients (6%) experienced
graft rejection between 13 and 1123 days (median,
74 days) after HCT, with 4 rejections occurring de-
spite administration of pentostatin followed by DLI.
After excluding patients who received DLI to prevent
graft rejection, data on T cell chimerism at day-14
were available for 7 graft rejectors and 170 nonrejec-
tors, and similar data for NK cells were available for 6
rejectors and 142 nonrejectors. The mean day-14 T
cell chimerism level was 14% in rejectors and 65%
in nonrejectors (P \ .0001), with corresponding
day-14 NK cell chimerism levels of 34% and 73%
(P\ .0001). Of the 7 rejectors among patients with
T cell chimerism levels available at day 14, 5 had
values \ 10%, 1 had a value between 10% and
50%, and 1 had a value between 50% and 75%. Of
the 6 rejectors among patients with NK chimerism
levels available on day 14, 2 had values \ 10%, 3
had values between 10% and 50%, and 1 had a value
between 75% and 90%. The percentages of patients
who were missing at least 1 ligand for donor NK
cell KIRs were similar in rejectors and nonrejectors
(82% vs 90%).GVHD
Grade II, III, and IV aGVHD occurring beyond
day 14 was diagnosed in 45%, 10%, and 4% of
patients, respectively. With chimerism modeled as
a categorical variable, the probability of grade II-IV
aGVHD increased with increasing levels of donor T
cells (P 5 .01; trend test), but not of NK cells
(P5 .38; trend test) (Table 3).When both day-14 donor
T cell and NK cell chimerism levels were included in
a model for grade II-IV aGVHD, the (nonstatistically
significant) association for donor NK cell chimerism
level became even less significant (P 5 .83; trend test),
whereas the association for T cell chimerism remained
statistically significant (P 5 .01; trend test). These ob-
servations remained qualitatively similar after adjust-
ment for the presence or absence of 1 or more ligands
for donor NK cell KIRs, as well as after adjustment
for the number of activating or inhibitory genes (data
not shown).
Extensive cGVHD was present in 52% of the pa-
tients. When donor chimerism levels were modeled
as average values for days 14, 28, and 42, no statistically
significant association was found between NK cell
level and cGVHD (P5 .80; trend test with chimerism
modeled as categorical variable), whereas a significant
association was found between high T cell level and
cGVHD (P5 .05; trend test). The results were similar
after adjustment for the presence or absence of 1 or
Table 2. Associations between Transplantation/Pretransplantation Factors and Donor T Cell and NK Cell Chimerism Level*
Factor NK Cell Chimerism T Cell Chimerism
Number of CD34 cells transplanted P 5 .004 (greater number transplanted, higher
chimerism levels)
P 5 .002 (greater number transplanted, higher
chimerism levels)
Number of T cells transplanted P 5 .06 (greater number transplanted, higher chimerism
levels)
P 5 .004 (greater number transplanted, higher
chimerism levels)
Bone marrow (vs G-PBMC) P 5 .007 (bone marrow lower 30%) P < .0001 (bone marrow lower 43%)
URD (vs related donor) P 5 .49 (URD lower 2%) P 5 .45 (URD lower 2%)
Disease category
Lymphoid malignancies — —
Myeloid malignancies P 5 .23 (myeloid lower 4%) P 5 .0006 (myeloid lower 11%)
Solid tumors P 5 .34 (solid lower 8%) P 5 .007 (solid lower 16%)
NK indicates natural killer; PBMC, peripheral blood mononuclear cells; URD, unrelated donor.
*P values were obtained from generalized estimated equations, using chimerism values measured at days 14, 28, and 42 after HCT.
Table 3. Associations between Day-14 Donor Chimerism
Levels and Acute GVHD
Patients with Acute GVHD/Patients at Risk, n (%)*
% Donor Chimerism
on Day 14 T Cells NK Cells
0-50 22/47 (47%) 10/20 (50%)
51-75 34/65 (52%) 24/42 (57%)
76-90 32/43 (74%) 31/53 (58%)
91-100 9/13 (69%) 16/25 (64%)
Trend test† P 5 .01‡ P 5 .38§
*Patients with GVHD or death before day 14 were excluded from the
analyses.
†P values adjusted for donor type (related vs unrelated).
‡P 5 .01 after adjusting for donor NK cell chimerism level.
§P 5 .83 after adjusting for donor T cell chimerism level.
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adjustment for the number of activating or inhibitory
genes.
Taken together, these results suggest an associa-
tion between GVHD and the tempo of donor T cell
engraftment, but not NK cell engraftment.
Relapse, achievement of complete remission,
NRM, and PFS
With a median follow-up of 4 years for surviving
patients, 107 patients relapsed/progressed between 4
and 1978 days (median, 166 days).When donor chime-
rism level was modeled as a continuous variable, no
significant association between donor T cell chime-
rism level and relapse was found (P 5 .10), whereas
high donor NK cell chimerism level was associated
with decreased risk of relapse in time-dependent anal-
yses (P 5 .0009; Table 4). The magnitude of the asso-
ciation was similar if the analysis was restricted to
patients with a day-14 chimerism level of $ 25%.
Furthermore, the associations between donor T cell
and NK cell chimerism levels and relapse risk were
qualitatively the same when the analysis was restricted
to patients with hematologic malignancies. The con-
clusions also were qualitatively the same after adjust-
ments for the presence or absence of 1 or more
ligands for donorNK cell KIRs, as well as for the num-
ber of activating or inhibitory genes (data not shown).
The risk of relapse was lower in patients who had all
ligands for donor NK cell KIRs compared with those
missing 1 or more ligands for donor NK cell KIRs,
but the difference was not statistically significant
(adjusted hazard ratio [HR] 5 0.74; 95% confidence
interval [CI] 0.39 to 1.41; P 5 .36) (Figure 1A). Table
5 gives the raw percentages of relapse according to the
specific missing ligand [33]. A formal statistical analy-
sis based on these specific ligands is not possible
because of the large number of unique categories; the
raw percentages in Table 5 do not suggest any striking
associations, however.
A total of 172 patients had measurable disease at
HCT, and 69 of them achieved complete remission(CR). The average CD3 donor chimerism level was
72% in those patients who achieved CR and 67% in
those who did not (P 5 .23).
A total of 64 patients died of a nonrelapse-associ-
ated cause between 20 and 2466 days (median, 230
days) after HCT. No statistically significant associa-
tions were found between donor T cell (P 5 .67), or
NK cell (P5 .21) chimerism level andNRMwhen chi-
merism was modeled as a continuous linear variable.
These results did not change after adjustments for
both the presence or absence of 1 or more ligands for
donor NK cell KIRs and the numbers of activating
or inhibitory genes (data not shown).
When chimerism level was modeled as a continu-
ous linear variable, high levels of both donor T cell
(P 5 .01) and NK cell (P\ .0001) chimerism were
associated with better PFS. The results were similar af-
ter adjustment for the presence of 1 ormore ligands for
donor NK cell KIRs and the numbers of activating or
inhibitory genes (data not shown). The risk of failure
for PFS was higher in patients missing at least 1 ligand
for donor NK cell KIRs compared with those not
lacking such ligands, but the difference was not statis-
tically significant (HR5 1.33; 95% CI5 0.81 to 2.20;
P 5 .26).





Day 14 T Cells NK Cells
0-50 1 1
51-75 0.35 (0.17-0.72; P 5 .004) 0.29 (0.10-0.82; P 5 .02)
76-90 0.48 (0.25-0.91; P 5 .03) 0.29 (0.13-0.63; P 5 .002)
91-100 0.50 (0.26-0.96; P 5 .04) 0.20 (0.09-0.45; P 5 .0001)
Trend test* P 5 .10 P 5 .0009
*P values obtained by the Cox model. Chimerism was modeled as
a time-dependent covariate. All models were adjusted for donor rela-
tionship (unrelated vs related), aggressive versus indolent disease,
HCT-CI, and previous autologous transplantation.
Figure 1. Probability of relapse in patients with all ligands for donor
NK cell KIRs compared with those lacking 1 or more such ligands.
Table 5. Associations between Matching of Recipient HLA
Class I Ligand toDonorNKCell KIR and Proportion of Relapse
Patients, n (%) Relapses, n (%)
Recipient has all ligands for donor
inhibitory KIR
28 (9.9) 11/28 (39)
Recipient misses one or more ligands
for donor inhibitory KIR
237 (84) 91/237 (38)
Recipient A3 or 112/donor 3DL2+ 67 (23.8) 27/67 (40)
Recipient Bw42/donor 3DL1+ 14 (5) 5/14 (36)
Recipient C12/donor 2DL2/3+ 7 (2.5) 2/7 (29)
Recipient C22/donor 2DL1+ 11 (3.9) 2/11 (18)
Recipient A3/112 and Bw42/donor
3DL2+ and 3DL1+
11 (3.9) 5/11 (45)
Recipient A3/112 and C12/donor
3DL2+ and 2DL2/3+
21 (7.4) 7/21 (33)
Recipient A3/112 and C22/donor
3DL2+ and 2DL1+
43 (15.2) 21/43 (49)
Recipient Bw42 and C12/donor
3DL1+ and 2DL2/3+
4 (1.4) 1/4 (25)
Recipient Bw42 and C22/donor
3DL1+ and 2DL1+
26 (9.2) 11/26 (42)
Recipient A3/112 and Bw42 and
C12/donor 3DL2+ and 3DL1+ and
2DL2/3+
3 (1.1) 1/3 (33)
Recipient A3/112 and Bw42 and
C22/donor 3DL2+ and 3DL1+ and
2DL2/3+
30 (10.6) 9/30 (30)
Unknown KIR genotype 17 (6) 5/17 (29)
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It has been commonly accepted that donor T cells
play important roles in engraftment, GVHD, and
graft-versus-tumor effects after HLA-matched HCT
in patients with malignancies [9]. The removal of T
cells from hematopoietic grafts by various T cell deple-
tion techniques generally is associatedwith higher graft
rejection rates, lessGVHD, andmore frequent relapse/
progression of underlyingmalignancies comparedwith
the use of unmodified grafts [34,35]. Consistent with
these previous observations, our patients with high
numbers of grafted T cells experienced rapid, high do-
norT cell chimerism,which in turnwas associatedwith
a lower rate of graft rejection, increased rates of
aGVHD and cGVHD, and a slightly (but not statisti-
cally significant) decreased risk of relapse.
The role of donor NK cells in these transplanta-
tion settings remains far less clear. One of the earliest
studies, of 175 patients receiving an HLA-matched
related marrow graft after conventional conditioning,
found relatively rapid recovery of NK cell function
but no correlation between the tempo of recovery
and the risk of GVHD, infection, or recurrence of ma-
lignancy [7]. Nonetheless, renewed interest in the role
of NK cells in the HCT setting was rekindled by find-
ings from investigators in Perugia, Italy, showing that
after HLA-haploidentical HCT, graft-versus-hostNK
cell reactivity was associated with lower rates of graft
rejection, aGVHD, and relapse in patients with acute
myelogenous leukemia (AML) [10]. A more recent
study by this group found similar incidences of
aGVHD in patients with or without graft-versus-
host NK cell reactivity, however [36].
The most robust predictor of donor versus recipi-
ent NK cell alloreactivity in the HCT setting has been
a matter of extensive debate. Based on experimental
observations, the Perugia investigators proposed that
all mature NK cells express at least 1 inhibitory recep-
tor for self HLA, and thus the presence or absence of
functional KIRs can be detected by HLA genotype[10,37]. Based on this hypothesis, that group devel-
oped a simple algorithm, known as the KIR ligand in-
compatibility model, in which comparison between
donor and recipient HLA class I genotype allows pre-
diction of NK alloreactivity. Several other groups have
retrospectively tested the KIR ligand incompatibility
model in patients given grafts from HLA-mismatched
URDs [17,18,38,39]. Although some of these studies
found a lower risk of relapse in patients with KIR
ligand incompatibility in the graft-versus-host direc-
tion [17,18], others failed to identify such an associa-
tion [38-40].
Given that HLA and KIR genes are encoded on
chromosomes 6 and 19, respectively, they are inherited
independently [41]. Consequently, 75% ofHCTs with
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URDs are KIR genotype–mismatched [41]. These
observations are the basis for the ‘‘missing KIR ligand
model,’’ in which donor–recipient NK cell alloreac-
tivity is predicted by analyses of donor KIR genotype
and recipient HLA genotype [42,43]. Both HLA-
matched and HLA-mismatched donor–recipient pairs
may have missing ligands. In support of this model,
one study found that early after transplantation, en-
grafted donor stem cells gave rise to a NK cell wave
that expressed the same repertoire as the donor cells
[14] and contained high frequencies of donor-versus-
recipient alloreactive NK cells in HCTs in which the
recipients lacked ligands for donor NK cell KIRs
[15]. Several studies have evaluated the missing KIR
ligand model in HLA-identical HCT, with differing
results. Although some of the studies found a lower
risk of relapse in patients missing 1 or more KIR
ligands [16,19], others failed to find such an association
or even found a detrimental effect of missing KIR
ligands [44,45].
Given the strong association between rapid post-
transplantation establishment of high donor NK cell
chimerism levels andbetter PFS reported in the current
study [20], along with previous data demonstrating the
importance of KIR ligands in HLA-haploidentical
transplantation [10], we explored whether immunoge-
netic factors possibly could provide additional infor-
mation on the mechanisms underlying donor NK
chimerism and, specifically, whether donor–recipient
HLA and KIR genotype information could predict
those patients who might have a higher probability of
achieving robust donor NK chimerism. Interestingly,
we found no association between missing 1 or more li-
gands for donor NK cells and risk of relapse. Further-
more, the qualitative association between prompt NK
cell engraftment and less relapse did not differ after ad-
justment for number of activating or inhibitory donor
KIR genes (which served as markers for KIR donor
haplotype). Several significant characteristics of our
study population might help explain this lack of associ-
ation of genotypewith outcome.Most importantly, the
conditioning and GVHD prophylaxis regimens and
the use of T cell–replete donor stem cells in our pa-
tients provided a setting that favored T cell reconstitu-
tion [46,47] and differed greatly from the regimens
used in theHLA-haploidentical transplantation setting
[10]. Both theHLA andKIR genetic systems are highly
polymorphic [48], and the organization of KIR genes
on haplotypes is complex [33]; examination of the clin-
ical impact of KIR ligands together with their cognate
receptors resulted in very small numbers of donor–
recipient pairs with each combination, and might
have limited our ability to evaluate their clinical impor-
tance. Likewise, although we found a lower risk of
relapse in those patients with all ligands for donor
KIRs compared with those missing 1 or more ligands,along with a greater risk of failure to achieve progres-
sion-free survival in patients missing at least 1 ligand
for donor KIRs compared with patients with all such
ligands, these differences were not statistically signifi-
cant. Examination of these questions in a larger trans-
plantation experience will be important in the future.
Analyses of recipient and donor KIR haplotypes are
ongoing to investigate a possible association between
KIR haplotype and HCT outcome after nonmyeloa-
blative conditioning, as has been observed in the mye-
loablative setting [33,49].
A previous study comparing KIR reconstitution in
patients given T cell–depleted or unmanipulated
grafts found that T cells in the graft altered HLA-
C–binding KIR reconstitution, whereas, interestingly,
reconstitution of KIR3/DL1, binding to Bw4, was less
affected by the number of T cells in the grafts [50].
This finding prompted us to investigate whether miss-
ing ligands for donor Bw4 would impact HCT out-
comes. Confirming the findings from analysis of all
KIR ligands together, we found no impact of a missing
ligand for KIR3/DLI on relapse risk and other HCT
outcomes.
Our main finding in the present study is that
prompt donor NK cell engraftment correlated with
low risk of relapse. This association was not affected
by donor type (related vs unrelated) or by disease cat-
egory. Our results are in agreement with recent find-
ings reported by Savani et al. [51,52] that rapid
versus slowNK cell recovery was associated with lower
risk of relapse and better overall survival (OS) in pa-
tients with chronic myelogenous leukemia (CML)
given T cell–depleted G-PBMCs after myeloablative
conditioning [51,52]. Interestingly, in those studies,
rapid NK cell recovery correlated not only with high
numbers of transplanted CD341 cells, but also with
higher numbers of donor total (inhibitory and activat-
ing) KIR genes [51,52]. It might be argued that prompt
NK cell engraftment after nonmyeloablative condi-
tioning can serve as a marker of ‘‘good graft function’’
without implicating donorNK cells in graft-versus-tu-
mor effects. But, this hypothesis is unlikely, because
previous studies have failed to identify a correlation
between the kinetics of granulocyte engraftment and
risk of relapse [3,20,23]. Furthermore, the association
between high donor NK chimerism levels and low
risk of relapse remained quantitatively similar when
the analyses were restricted to patients with day-14
NK chimerism levels . 25%, this demonstrating
that this association was not affected by patients with
very poor engraftment (who were likely to have graft
rejection and thus relapse). Importantly, prompt do-
nor NK cell engraftment was not associated with
higher incidence of aGVHD or cGVHD, suggesting
that initiation of NK cell adoptive immunotherapy
early after HCT could be a promising approach to sep-
arate graft-versus-tumor effects from GVHD.
Biol Blood Marrow Transplant 15:580-588, 2009 587NK Cells after Nonablative HCTIn conclusion, we found that robust engraftment
of donor NK cells correlated with low risk of graft
rejection, low risk of relapse, and high PFS, but not
with aGVHD. These associations did not depend
on donor NK cell alloreactivity. The clinical impor-
tance of recipient ligand and donor KIR haplotypes
on posttransplantation donor NK chimerism and
HCT outcomes merits further study.ACKNOWLEDGMENTS
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